A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. - Wikidata - wikimedia - TriplyDB

A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

http://www.wikidata.org/entity/Q33519507

about

A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans Native functionality and therapeutic targeting of arenaviral glycoproteins Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development Universal vaccines: shifting to one for many VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource.Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials Properties of MHC class I presented peptides that enhance immunogenicity Human CD8⁺ and CD4⁺ T cell memory to lymphocytic choriomeningitis virus infection.Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts.Universal vaccines: shifting to one for many or shooting too high too soon!Universal fungal vaccines: could there be light at the end of the tunnel?Recent progress towards development of a Shigella vaccine.Analyzing the effect of peptide-HLA-binding ability on the immunogenicity of potential CD8+ and CD4+ T cell epitopes in a large dataset.Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses.Arenaviruses: Hemorrhagic Fevers

P2860

Q24611383-8FFCD4D4-866B-4EE1-8F6B-58FAFD23496E Q26827679-8424899E-2C29-405C-9A40-486552A18101 Q30226873-7F5725FB-DA9E-4BDA-A5DB-64635508E283 Q30392373-9C5A805C-286C-4061-AE7C-80C2C0E23941 Q33723534-1BCC734E-E60A-4CFE-93D7-F75320EFE35D Q33892499-D0B8C773-20DE-4E6C-9145-F90A5A2641EF Q33909096-47978C5B-9E15-4348-A662-275C7A9B590B Q34586710-3137DAAE-24EC-4FC2-ACF0-44B371A6DA82 Q34671806-4AB92ED4-B02A-47AF-886F-E00C816AB15A Q35034097-F41D846A-7403-4892-9E50-87AED253B99D Q35531223-77D91812-5797-40ED-8B88-F87105BE5642 Q36083978-A98F972A-D7DD-49AC-8970-73F4245D0FE5 Q36140086-479E5E58-AD2D-45E6-8D2E-79E251F14318 Q37919551-FD1E7DC4-1DC5-4B22-B52C-C8CE2C1D0672 Q38038044-A22B650F-FF17-4386-95AF-3D8A4BD208B2 Q38068954-210B6245-60CE-44A2-983E-1050FFAB9490 Q39838760-05A15420-CDD5-43AC-B4DD-3D2745F785A8 Q39849181-9BF34D8F-1C63-486B-81C1-69A91AD2F547 Q55306089-9ABD7282-E442-494B-B695-57B36F79B221 Q56763187-2BC94906-64C9-4553-BB87-D6705D413EF8

P2860

A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

http://www.wikidata.org/entity/Q33519507

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A multivalent and cross-protec ...... associated with human disease.

@ast

A multivalent and cross-protec ...... associated with human disease.

@en

A multivalent and cross-protec ...... associated with human disease.

@nl

type

label

A multivalent and cross-protec ...... associated with human disease.

@ast

A multivalent and cross-protec ...... associated with human disease.

@en

A multivalent and cross-protec ...... associated with human disease.

@nl

prefLabel

A multivalent and cross-protec ...... associated with human disease.

@ast

A multivalent and cross-protec ...... associated with human disease.

@en

A multivalent and cross-protec ...... associated with human disease.

@nl

P1433

Q33519507-E8756254-D37A-4B36-AB13-6CFD386C927C

P1476

Q33519507-6B793A82-B698-4FFD-A90B-2FF549EDB6C1

P2093

Q33519507-33764A4F-BDB9-4089-BEFC-56BD0C3367A7

Q33519507-3A511F19-649B-479C-A8A3-E6A8B1E41B7F

Q33519507-42349718-0D41-4BAB-B501-E91AD77E8D39

Q33519507-4F3E445C-5F2E-43A7-B84D-807E6925F75F

Q33519507-5E33181D-C9C8-4B62-B8DF-82F2E2898EB9

Q33519507-6A7AAB9A-38AE-4177-935F-B6EB56278DB3

Q33519507-7086AB83-19B2-4498-8913-CC049BE8C766

Q33519507-716243CC-B94B-4D7C-9047-805FFD710770

Q33519507-78F1CBDA-C28C-4A24-A8B9-1D4C4592D00A

Q33519507-9075C339-8024-4A8A-A16F-F42ABD36FD57

P2860

Q33519507-01F3E8CC-98A8-4683-8FBD-DA3A1D9E83E0

Q33519507-0F33189F-9180-4DE6-AC62-F3646D1D50B7

Q33519507-17270ED6-B8DC-4664-8C8D-95A626936225

Q33519507-1741DDA8-152C-423B-9DDA-69CE44005C49

Q33519507-299A5FA9-1C5D-4666-A12D-DEE83F4FEE35

Q33519507-2BCAF024-89A5-49F3-808E-2AC3B7108E96

Q33519507-48F41B8F-DC3E-4B4A-9788-AFC5D232B494

Q33519507-4ABB4B86-4032-4147-BAA3-DD9DDDBDC651

Q33519507-4BA9BD9A-E9F4-4898-8D5F-FB1660DAF364

Q33519507-4F7890F3-DD23-4387-A71A-0F3445821128

P304

Q33519507-88766282-7478-4A74-8A42-4F9FD21C9BAF

P31

Q33519507-7279C07F-7D51-498E-AA87-CF5DA8EC9A71

P356

Q33519507-F702A16F-15A4-4630-AB5A-9C33A12F562E

P433

Q33519507-46EE30B0-B5C9-4F48-898E-75D649516262

P478

Q33519507-62418638-DEAE-41D0-95B0-7DF46FBEBBA2

P50

Q33519507-0DDA3A5A-2084-44C5-80A5-9D6E950B5522

Q33519507-133DE101-DA10-4185-BA5A-22F70142CA71

Q33519507-320995BA-9B29-4F72-9ADC-DF9492D33B9F

P577

Q33519507-33AE82F6-A6C3-434D-835A-9BC4ADDC4347

P5875

Q33519507-2061E0B2-843A-4040-B4F3-B97A1CF2C150

P698

Q33519507-3AC6AD1B-24F5-43A9-A831-C076A81E27BA

P932

Q33519507-90F925FD-CB81-43E6-8B8C-35811A3B27FE

P356

JOURNAL.PPAT.1000695

P1433

P1476

A multivalent and cross-protec ...... associated with human disease.

@en

P2093

Carla Oseroff

http://www.w3.org/2001/XMLSchema#string

Howard Grey

http://www.w3.org/2001/XMLSchema#string

Huynh-Hoa Bui

http://www.w3.org/2001/XMLSchema#string

Jason A Greenbaum

http://www.w3.org/2001/XMLSchema#string

Jason Botten

http://www.w3.org/2001/XMLSchema#string

Jeff Alexander

http://www.w3.org/2001/XMLSchema#string

Joey Ting

http://www.w3.org/2001/XMLSchema#string

John Sidney

http://www.w3.org/2001/XMLSchema#string

Josie Babin

http://www.w3.org/2001/XMLSchema#string

Lo Vang

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa

Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia

Global epidemiology of hepatitis C virus infection

Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak

Pandemic preparedness: toward a universal influenza vaccine.

Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice.

Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules.

Phylogeny of the genus Arenavirus.

Predicting population coverage of T-cell epitope-based diagnostics and vaccines.

Congenital lymphocytic choriomeningitis virus infection: spectrum of disease.

P304

e1000695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1000695

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Sette

P577

2009-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40697093

http://www.w3.org/2001/XMLSchema#string

P698

20019801

http://www.w3.org/2001/XMLSchema#string

P932

2787016

http://www.w3.org/2001/XMLSchema#string